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Abstract
Molecular surveillance of HRSV in Belgium for 15 consecutive seasons (1996–2011) revealed a shift from a regular 3-yearly
cyclic pattern, into a yearly alternating periodicity where HRSV-B is replaced by HRSV-A. Phylogenetic analysis for HRSV-A
demonstrated the stable circulation of GA2 and GA5, with GA2 being dominant over GA5 during 5 consecutive seasons
(2006–2011). We also identified 2 new genotype specific amino acid mutations of the GA2 genotype (A122 and Q156) and 7
new GA5 genotype specific amino acid mutations (F102, I108, T111, I125, D161, S191 and L217). Several amino acid
positions, all located in the second hypervariable region of HRSV-A were found to be under positive selection. Phylogenetic
analysis of HRSV-B showed the circulation of GB12 and GB13, where GB13 represented 100% of the isolated strains in 4 out
of 5 consecutive seasons (2007–2011). Amino acids under positive selection were all located in the aminoterminal
hypervariable region of HRSV-B, except one amino acid located in the conserved region. The genotype distribution within
the HRSV-B subgroup has evolved from a co-circulation of multiple genotypes to the circulation of a single predominant
genotype. The Belgian GB13 strains circulating since 2006, all clustered under the BAIV branch and contained several branch
specific amino acid substitutions. The demographic history of genotypes GA2, GA5 and GB13 demonstrated a decrease in
the total GA2 and GA5 population size, coinciding with the global expansion of the GB13 population. The emergence of the
GB13 genotype resulted in a newly established balance between the predominant genotypes.
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Introduction
Human respiratory syncytial virus (HRSV) is the most
important viral agent causing serious lower airway infections in
children less than 2 years old. HRSV can be divided into two
subgroups, HRSV-A and HRSV-B and these subgroups harbour
several genotypes, which represent clusters of co-circulating strains
[1–7]. Viruses of the two antigenic groups commonly produce
epidemics and annual epidemics that are characterized by the
circulation of several genotypic strains. Genotyping of HRSV
strains have historically been based on sequence data of the
variable G glycoprotein [3]. The G protein has been shown to be
the most divergent between HRSV-A and B subgroups with 67%
identity on the nucleotide level and 53% similarity on the deduced
amino acid level [8]. In addition, the G protein is one of the targets
of neutralizing antibodies and continues to incorporate mutations
due to existing immunological pressure [9–12]. For genotyping
purposes, the hypervariable ectodomain of this protein has been
selected as a reliable region for the entire G gene variability [3,5].
This carboxyterminal domain encloses a first variable region
starting at nucleotide position 284–459 for HRSV-A and 194–459
for HRSV-B. This domain is followed by a conserved cystein
cluster and a second variable region located at nucleotide 649–918
for HRSV-A and nucleotide 652–921 for HRSV-B [8,11,13]. In
1998, Peret and coworkers defined HRSV genotypes based on the
topology of phylogenetic trees of HRSV variants. For HRSV-A
the genotypes GA1, GA2, GA3, GA4 and GA5 were identified
with intergenotypic differences that ranged from 10–28% at the
amino acid level. For HRSV-B, GB1 to 4 were distinguished and
intergenotypic differences at the amino acid level ranged from 7–
19% [3]. Previous genotyping efforts in Belgium introduced a
genotype classification based on a gene segment of 629 bp for
HRSV-A and 724–762 bp for HRSV-B comprising both hyper-
variable regions and the conserved region [6,7]. Phylogenetic
analyses have led to the distinction of 6 clusters that were assigned
to genotypes BE/A1, GA1 to GA5, within the HRSV-A subgroup
and GB1 to GB13 genotypes were identified within subgroup B.
The genotype assignment of HRSV-A and –B strains was partially
based on the genotype ascription of previous strains [3–5,14] The
GB13 genotype is characterised by a 60-nucleotide duplication
and 6- nucleotide deletion and corresponds to the BA genotype
described by Trento and co-workers [15].
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Previous HRSV epidemics studied in Belgium showed that 2
subgroup A dominant seasons were followed by a subgroup B
dominant season. Although it is difficult to explain the periodicity
of the subgroup dominance, the dominant circulation of one
subgroup over the other most likely results from the interplay of
the pre-existing immunity in the community and the genetic and
antigenic properties of the HRSV virus to evade the immune
response. Over the past decades (1984–2006), the genotype
circulation in Belgium was dynamic with circulation of BE/A1,
GA1, GB1, GB2, GB3, GB4, GB5 and GB7 in the eighties and
nineties [16]. These genotypes disappeared out of the population
and were replaced by the predominant circulation of GA2, GA5,
GB12 and GB13 genotypes.
In this study, HRSV seasonal epidemic dynamics in Belgium
were monitored over a five-year period (2006–2011) investigating
subgroup patterns and stability of genotypes previously circulating
in Belgium. This epidemiological data (2006–2011) added to the
previous epidemiological data obtained during 10 epidemic
seasons (1996–2005), and allowed the interpretation of the HRSV
dynamics over 15 consecutive years in Belgium [16]. Further, the
genetic variability, phylogenetic relatedness and demographic
history of HRSV-A and -B strains were investigated by mapping
genetic diversity, performing selective pressure analysis and
coalescent analysis that demonstrated the evolution of the virus
population size over time.
Materials and Methods
Sample Collection
One-thousand-fifty-nine nasopharyngeal samples (NPS) from
patients experiencing respiratory infections were collected during 5
HRSV epidemic outbreaks (2006/2007 till 2010/2011). Samples
were acquired from patients invoking medical attention in the
hospital for respiratory tract infection. Nine-hundred-ninety-three
were obtained from the University Hospital of Leuven and 66
from the O.L.V. Hospital in Aalst. Both hospitals are located in
Flanders and are situated 60 km from each other. All samples were
HRSV positive because they had been previously tested positive
by RSV antigen test (BinaxNOW RSV test, Medical Innovations
Inc., Ireland), ‘in house’ PCR or qPCR before arriving at the
laboratory. Nine-hundred-seventy-four samples were successfully
subgrouped (Table 1) by means of qRT-PCR.
RNA Extraction
Viral RNA was extracted from 140 ml of NPS by using the
QIAmp viral RNA mini kit (Qiagen, Westburg, The Netherlands).
RNA was extracted according to the manufacturers instructions
and eluted in 60 ml elution buffer.
Subgrouping
A multiplex qRT-PCR with a subgroup specific primer and
probeset for HRSV-A and –B as described previously [16] was
used to identify the subgroup of the virus strain.
RT-PCR
The carboxyterminal region of the G protein was amplified by
using the One-Step RT-PCR (Qiagen, Westburg, The Nether-
lands). The HRSV-A forward and reverse primer, G267FW and
F164RV and the HRSV-B forward and reverse primer BGF and
BGR separately to polyacrylamide gel electrophoresis and
visualised under UV light by staining with ethidium bromide.
Nucleotide Sequencing
The amplified PCR products were purified using the innuPREP
PCRpure kit (Analytik Jena, Germany) and eluted in 20 ml elution
buffer. Cycle sequencing was performed in forward and reverse
direction using the ABI PRISM Big Dye Termination Cycle
Sequencing Ready Kit (Applied Biosystems). In addition to the
PCR amplification primers, the G516R (59-GCTGCAGGGTA-
CAAAGTTGAAC-39) and G284F (59-ACCTGACCCA-
GAATCCCCAG-39) for HRSV-A and BGF3 (59-AGAGACC-
CAAAAACACYAGCCAA-39) and BGR3 (59-
ACAGGGAACGAAGTTGAACACTTCA-39) primers for
HRSV-B were used to assure complete consensus sequence of
the amplicon. Sequence data was generated on the ABI3130xl
Genetic Analyzer (Applied Biosystems). Sequences were manually
edited and multiple sequence alignments were generated using the
Clustal X 2.0.12 version [17]. Identical nucleotide sequences were
identified by the DAMBE software version 4.2.13 [18]. Pairwise
distances were calculated between unique sequences in MEGA5
[19]. Sequences were deposited in GenBank under the accesion
numbers [JX645776-JX645982].
Phylogenetic Analysis
We generated sequences of 629 bp and 724–762 bp for HRSV-
A and HRSV-B respectively, to investigate the phylogenetic
relationships between viral strains. Phylogenetic trees were
constructed by the Neigbour Joining method using the MEGA5
software [19]. Bootstrap values were calculated based on 1000
replicates.
Selective Pressure Analysis
We used a random effects likelihood (REL) approach based on a
codon substitution model that allows for variation both in non-
synonymous (dN) and synonymous rates (dS) to detect the selective
pressure at an individual site in the G gene. This method fits a
Table 1. Subgroup dominance per epidemic season.
Epidemic season
No. RSV positive
samples
No. (%) of samples
typed* No. (%) of HRSV infections*
HRSV-A HRSV-B HRSV-A & -B
2006/2007 128 127 (99.2) 9 (7.0) 111 (86.7) 7 (5.5)
2007/2008 140 126 (90.0) 101 (72.1) 17 (12.1) 8 (5.7)
2008/2009 252 231 (91.6) 50 (19.8) 149 (59.1) 32 (12.7)
2009/2010 402 389 (96.8) 271 (67.4) 114 (28.4) 4 (1.0)
2010/2011 137 101 (73.7) 84 (61.3) 17 (12.4) 0 (0.0)
*Percentages are calculated to the total number of RSV positive samples that were typed.
doi:10.1371/journal.pone.0060416.t001
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general bivariate distribution of dN and dS substitution rates across
sites (each composed of three classes) and then infers the class to
which each individual site belongs. The REL approach was
applied using the HyPhy program and positive selected sites were
detected by using empirical Bayes methods. Bayes factors .20
expressed as Log [BF{NS|S .1|S}] were used as a cut-off to
identify positively selected sites.
Bayesian Skyride Analysis
To estimate the effective population size dynamics through time
we employed the Bayesian skyride approach as a flexible
coalescent model [20]. The Bayesian skyride achieves temporal
smoothing of the effective population size by exploiting Gaussian
Markov random fields in a Bayesian framework implemented in
the BEAST software version 1.7 [21]. We compiled a dataset for
HRSV-A based on the GA2 and GA5 genotyped strains available
in GenBank (Table S1) and the Belgian isolates sequenced in this
study. The nucleotide sequence covered a 264 bp fragment of the
second hypervariable region. For HRSV-B, sequences designated
as GB13 genotype were used. Here, we used the same dataset as
published by Trento and co-workers with in addition the Belgian
sequence data from the epidemic seasons 2006–2011 (Table S2)
[22]. For these analyses a nucleotide sequence alignment of
330 bp, comprising the second hypervariable region of the HRSV-
B subgroup was employed. Sequences with a known year of
isolation were included in the datasets and for the sequences with
an unknown circulation date; the year of isolation was estimated
[23].
Results
Age Distribution
The major population groups afflicted by HRSV infections are
babies under the age of 12 months (81.5%), followed by patients
older than 24 months and infants between 13 and 24 months.
When looking at the age group older than 24 months in more
detail, a diversification between several subpopulations can be
made. This group consisted of 56.4% toddlers (,5 years), 23.1%
children (5.,13 years), 5.1% adolescents (13.,26 years), 6.4%
adults (28.,60 years) and 6.4% elderly (65 years and older). In
the group of adolescents, 4 patients were being followed at the
paediatric oncology division and one patient had a history of
paediatric immune deficiency. Regarding the general number of
patients during 15 epidemic seasons in Belgium, the number of
infected patients during the 2009/2010 season is remarkably high
(Figure 1). During this season, the pandemic swine influenza virus
(H1N1) was emerging worldwide, possibly alarming parents for the
manifestation of respiratory infections in their children (Figure 1).
This vigilance may have resulted in patients seeking medical
attention much faster.
Patients with Multiple and Prolonged HRSV Infections
Fourteen paediatric patients experienced two or three HRSV
infections within the timeframe of 5 epidemic seasons (2006/
2007–2010/2011) (Table 2). In 8 of the 14 cases the secondary
infection was caused by a strain of the homologous subgroup: 4 A-
A, 3 B-B and 1 A&B-A&B. Five patients were infected by a strain
of the heterologous subgroup: 1 A-B, 3 B-A and 1 B- A&B co-
infection. One patient encountered a HRSV infection during 3
consecutive epidemic seasons (07/08, 08/09 and 09/10) of which
the second infection was caused by the heterologous subgroup.
The third infection was induced by a strain of the homologous
subgroup, compared to the primary infection. For 3 patients, the
secondary infection was caused by a strain of the same genotype.
The homologous A-A reinfection in table 2 was also a homologous
GA2 genotype reinfection. Sequence comparison at the amino
acid level revealed A113T, A130I, Q142L, P234L, E240K and
N273Y alterations in the G protein when comparing the 2009 to
the 2011 strain. Two patients were re-infected by the homologous
GB13 genotype. Sequence comparison of the HRSV-B G protein
revealed the incorporation of several amino acid substitutions. For
the patient with a primary infection in 2006 and a secondary
infection in 2008, the amino acid substitutions S138T, R153K,
V171F, Q180R, N204R, K205E, A251V, T256I, S267L and
L277S were observed. For the second patient, initially infected in
2008 and re-infected in 2010, the amino acid changes R98K,
L124S, K136R, T138S, R153K, L219P, I256T, E261G, L267S
and L277S were present.
In 2 patients, infected during the 2009/2010 season, a
prolonged virus shedding was observed. A 2-month-old boy was
infected with HRSV-A and nasopharyngeal samples remained
positive for 2 months (December 2009 till February 2010). A 6-
month-old girl was infected by HRSV-B and respiratory samples
were positive from January 2010 till the end of March 2010. The
medical history of these patients indicated that they were under
attention of the oncology division of the hospital and most likely
were suffering from immunological failure.
Seasonality
HRSV seasons in Belgium traditionally set off in the fall
(October) and can last till early spring (March) (Figure 1). Usually,
an epidemiological peak is reached around week 50 in the winter.
Remarkably, the epidemiological season of 2008/2009 was
characterised by an early onset and an advanced epidemiological
peak in week 47. Epidemic outbreaks have a mean duration of
approximately 22 weeks.
Subgroup Dominance
Subgrouping by means of qRT-PCR demonstrated a yearly
alternating dominance between HRSV-B and HRSV-A during
the epidemic season of 2006/2007 till 2009/2010 (Table 1).
HRSV monitoring over 15 consecutive years has indicated a
recurrent subgroup pattern of AAB during 9 out of 15 outbreaks
(1996–2005) (Table 3). This temporal periodicity was replaced by
an AB sequential repetition, in the four epidemics following (2006–
2010). The latter season was followed by a second HRSV-A
dominant season 2010/2011.
Phylogenetic Analysis HRSV-A
A total of 227 (44.2%) out of 515 HRSV-A strains were
sequenced. One hundred and two sequences represented unique
strains and the remaining 125 strains were found identical to other
circulating strains. Clustering within the subgroup A with previous
genotyped strains [3,5] demonstrated the circulation of the GA2
and GA5 genotypes (Figure 2), with a clear dominance of GA2
over GA5 (Table 3). Belgian HRSV-A sequences isolated between
2006 and 2011 diverged in a range of 0.2–14.4% at the nucleotide
level and in a range of 0.5–25.5% at the amino acid level. The
deduced amino acid sequence of these strains showed a G protein
of 297 amino acids within the GA2 genotype and a G protein of
298 residues within the GA5 genotype (Figure 2).
Genotype Specific Amino Acid Mutations within
Subgroup A
GA2 and GA5 are characterised by genotype specific amino
acid mutations [24,25]. All Belgian GA2 strains had the previous
reported T269 and S289 amino acid substitution (Figure S1). The
Circulation of HRSV in Belgium
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amino acid mutations A225, N250, S251, T274, I279, I295 and
D297 were recognized in the second hypervariable region of the
GA5 classified strains. Since we sequenced the nearly complete
carboxyterminal ectodomain, including the first hypervariable
region and the conserved region, we were able to recognize several
other genotype specific amino acid mutations. GA2 strains were
characterised by the A122 and Q156 amino acids. Botosso and
colleagues report the L215P, R244Lis, H266Y, D297K and
STOP298W mutation, fixed in the GA2 genotype. All Belgian
GA2 strains isolated between 2006 and 2011 retained or mutated
back to the original amino acid except for residue D297K [26].
We were able to differentiate GA5 from GA2 by the presence of
F102, I108, T111, I125, D161, S191 and L217 at the amino acid
level.
Selective Pressure Analysis HRSV-A
Amino acids located at positions 237 (log BF= 4.4), 238 (log
BF= 4.5), 244 (log BF=5.06) and 262 (log BF= 5.03) were
identified to be under diversifying selection. These positive selected
sites are all located in the second hypervariable region of the G
protein. None of the positive selected sites were serines or
threonines, but several different amino acids were found at sites
under positive selection: D/N/Y/H at position 237, T/P/F/I at
position 238, R/G at position 244 and E or K at position 262.
Phylogenetic Analysis HRSV-B
The partial G gene sequence (nt 177 to 900 according to
reference strain WV/B1/85 accession number AF013254) of 213
(52.7%) out of 408 subgroup B isolates was determined and 105
sequenced strains were unique. One-hundred-and-eight sequences
were identical to other circulating strains shown in Figure 3.
Belgian isolates collected during the epidemic seasons of 2006 till
2011 had pairwise distances in the range of 0.1–7.3% at the
nucleotide level and differed in a range of 0.4–10.8% at the amino
acid level. Phylogenetic analysis demonstrated the circulation of
two genotypes: GB12 and GB13. Two isolates remained
unclassified (BE/6904/07 and BE/8773/09) (data not shown).
The GB13 genotype is the predominating genotype of the
circulating strains during the past 5 HRSV epidemic seasons
(Figure 3). All GB13 strains circulating from 2006/2007 till 2010/
2011 were circulating under the BAIV lineage (Figure 4).
Amino Acid Analysis of HRSV-B
Protein lengths of 215, 235, 295, 296, 310, 312 and 317 residues
were predicted based on the deduced amino acid sequence of the
HRSV-B isolates (Figure S2). Remarkably, in all 5 seasons, the G
protein length of 310 amino acids was dominant. The G protein
polymorphisms result from genetic variation created by the
presence of nucleotide mutations, a 6-nucleotide deletion, a 60-
Figure 1. Seasonality of HRSV in Belgium (2006–2011).
doi:10.1371/journal.pone.0060416.g001
Table 2. HRSV re-infections.
No. of HRSV re-infections
A–A A–B B–B B–A AB–AB B–A&B B–A–A
4 (09/10–10/11)** 1 (07/08–08/09) 1 (06/07–08/09)* 1 (07/08–07/08) 1 (06/07–08/09) 1 (06/07–07/08) 1 (07/08–08/09–09/
10)
1 (08/09–08/09) 2 (08/09–09/10)
1 (08/09–10/11)*
*Primary and secondary infections were caused by both strains of GB13 genotype **For 1 of the 4 re-infected patients, primary and secondary infections were caused by
strains of GA2 genotype. For the other reinfections, genotypes of the primary and/or secondary strain are undetermined since G gene nucleotide sequence was not
available. Epidemic season of primary, secondary or tertiary infection are indicated between brackets. All secondary infections occurred within 2 to 24 months. The
tertiary infection occurred after 11 months (B–A–A).
doi:10.1371/journal.pone.0060416.t002
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nucleotide duplication and the alternating use of three different
stop codons (Figure S2). In addition to this genetic variety, we
report a new 6-nucleotide insertion (GAAAAA) at nucleotide
position 678 that was identified in two isolates (BE/950858/08
and BE/944484/08) clustering in the GB13 genotype, during the
epidemic season of 2008/2009 (Figure S2). This in-frame-insertion
is located in-between the 6-nucleotide deletion and the 60-
nucleotide duplication and codes for the amino acids glutamine
acid and lysine. In these strains the first stop codon was
terminating and an amino acid length of 312 residues was
predicted for the G glycoprotein. For 2 isolates, a nucleotide
mutation led to the premature introduction of a stop codon
resulting in a truncated G protein at the carboxy-terminal end. For
isolate BE/404/10, the mutation AAGRTAG was responsible for
a predicted protein length of 235 amino acids. The mutation
AAARTAA introduced a stop codon at amino acid position 216,
resulting in a shortened G protein of BE/5351/08. For the BE/
7848/10 strain, the presence of the 6-nucleotide-deletion, 60-
nucleotide-duplication and CAARTAA terminating mutation
resulted in the amino acid length of 296 residues. Within the
GB13 genotype, predicted protein lengths of 310 and 317 amino
acids can be explained by the use of the first and third stop codon,
respectively. Two strains, BE/6907/07 and BE/8773/09, had
distinct predicted protein lengths of 295 and 299 residues resulting
from second and third stop codon usage. The amino acid length of
295 amino acids was associated with the GB12 genotype.
Genotype Specific Amino Acid Mutations within
Subgroup B
All Belgian GB13 strains were characterised by the T229I and
S247P substitution (Figure 4) and were classified as BA-IV based
on clustering with isolates from Buenos Aires [22,27] and South
Africa [28]. All Belgian isolates contained the characteristic BA-IV
H287Y substitution except for BE/6886/06, BE/8933/09 BE/
9364/09 BE/3374058/10 BE/5394/08 BE/5489/08 BE/
956911/08 BE/950755/08 and BE/94/07, BE/8845/09, BE/
1649/10 and BE/333/11 (indicated in Figure 4 by *). However,
several strains of the BA-IV branch (BE/6548/10, BE/3354412/
10, BE/404/10, BE/884/09, BE/7852/10, BE/6734/09, BE/
5533/08, BE/6504/08, BE/5149/08, BE/94/07, BE/6797/07,
BE/6007/07, BE/7176/07 and BE/5354/07) also contained the
BA-II associated L219P substitution. The BE/936751/08 strain
contained the P231Q amino acid substitution associated with BA-
V. The T270I substitution linked with branches BA-III to -V was
also detected in several isolates (BE/5150/08, BE/9004/09, BE/
1346/10, BE/9295/09, BE/9109/09 and BE/3301859/09).
Within the BA-IV branch, 6 additional substitutions (L223P,
STOP316Q, Q268L/P, E292G, Q313STOP and V271A) were
associated with the designation of subbranches: BAIVa, BAIVb,
MAD-II, MAD-III, INDIA and BRAZIL [22]. The L223P
Figure 2. Phylogenetic tree of HRSV-A strains. The phylogenetic
tree was constructed based on a 624-nucleotide fragment of the G
protein, consisting of the two hypervariable regions. The nucleotide
sequences of the Belgian strains isolated during 5 consecutive epidemic
seasons (2006–2011) were compared with reference strains from Italy
(ITA), Madrid (MAD), Montevideo (MON), West Virginia (WV) and
Birmingham (BIR). The outgroup is represented by the Long strain.
Bootstrap values are indicated at the internal nodes and are calculated
for 1000 replicates by using the neighbour joining method. Only
bootstrap values .70 are shown. The numbers between brackets are
the number of strains identical to one shown in the tree. The amino
acid lengths predicted for the G protein are indicated next to the
Belgian isolates. For both the GA2 and GA5 genotypes, a strong
temporal clustering of the strains per epidemic season is observed.
doi:10.1371/journal.pone.0060416.g002
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substitution was found in all Belgian BAIV strains except for BE/
333/11 and BE/5437/08. The Q268L/P substitution was not
found in the Belgian GB13 isolates. The E292G substitution was
found in a cluster of 12 strains. All Belgian strains had the
Q313STOP mutation with the exception of BE/7852/10, BE/
5691/08, BE/5213/08, BE/954893/10, BE/8845/09, BE/8923/
06, BE/5449/07, BE/6156/07, BE/7163/06 and BE/6726/07.
The V271A substitution, located in the duplicated region was also
frequently detected, but not in the cluster of 12 strains that also
had the E292G substitution and BE/1649/10, BE/6649/06 BE/
6504/08, BE/939189/08, BE/6259/08, BE/7163/06 and BE/
6726/07.
Recently, Dapat and colleagues suggested a reclassification of
the BAIV branch, different from the subclassification proposed by
Trento and co-workers, into BAIV, BA7, BA8 and BA9 [29].
They also reported the identification of a new BA10 branch. The
BA7 branch was correlated to E226G and L223P substitution.
Three isolates BE5351/08, BE/6504/08 and 939189/08 con-
tained the E226G mutation.
The S267L substitution is shared by a cluster of 28 strains
(indicated in red in Figure 4). Eighteen of these 28 strains also had
the S297F substitution. In addition, 7 strains (BE/5423/08, BE/
6953/07, BE/5312/08, BE/46/08, BE/7269/06, BE/6346/06
and BE/6649/06) not clustering in the S267L group, also
contained the S297F substitution. The I281T is shared by a
separate branch of 5 strains indicated in turquoise in Figure 4.
These aforementioned substitutions (S267L, S297F and I281T)
are characteristic for the BA9 branch. However, in our tree, the
S267L substitution and the I281T substitution are shared by 2
separate clusters. BA10 is distinct by the substitutions E292G,
E226D, T289I and S269P. Seven strains of the aforementioned
E292G cluster also had the E226D amino acid substitution in
common (indicated in blue Figure 4). Three strains of this cluster,
also shared the T289I substitution. These 3 substitutions E292G,
E226D and T289I have been linked to the branch BA10 [29].
Selective Pressure Analysis HRSV-B
Positive selected sites were identified at amino acid positions
T73, V76, T83, T92, T/I139, R/H151 and V171 (corresponding
to strain WV/B1/85) with Log BF= 3.2. Remarkably, all these
sites are located in the first hypervariable region of the G protein,
with the exception of amino acid position 171, which is located in
the conserved region. The threonines located at positions 76 and
171 were checked for O-glycosylation using the NetOglyc 3.1
program but the predicted potential of glycosylation was below the
threshold, providing no evidence of O-linked sugar chains.
Demographic History of GA2, GA5 and GB13 Genotypes
Worldwide
The population size dynamics of GA2, GA5 and GB13 were
estimated using Bayesian skyride analysis including strains isolated
Figure 3. Phylogenetic tree of HRSV-B strains. The phylogenetic
tree was constructed based on a 708–762-nucleotide fragment of the G
protein, consisting of the two hypervariable regions. The nucleotide
sequences of the Belgian strains isolated during 5 consecutive epidemic
seasons (2006–2011) were compared with reference strains from
Buenos Aires (BA), Belgium (BE) and South Africa (SA). The outgroup
is represented by the WV/B1/85 strain. Bootstrap values are indicated at
the internal nodes and are calculated for 1000 replicates by the
neighbour joining method. Only bootstrap values .70 are shown. The
numbers between brackets are the number of sequences identical to
the sequence shown in the tree. The amino acid lengths predicted for
the G protein are indicated next to the Belgian isolates. The isolates
with no predicted G protein length indicated consisted of 310 residues.
doi:10.1371/journal.pone.0060416.g003
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in different parts of the world. The combination of the GA2 and
GA5 nucleotide dataset, encompassing the second hypervariable
region of the G protein, resulted in the skyride plot for HRSV-A
(Figure 5). This estimate of population size through time for
HRSV-A was compared to the demographic history of GB13. The
Bayesian skyline plots clearly demonstrated an expansion for the
GB13 genotype after 1998. This expansion levelled of and was
followed by a period of roughly constant population size.
Interestingly, at the time point that the GB13 population size
attained a relatively high level, the population size of the HRSV-A
genotypes underwent a decrease. After this decrease, the total
population size of GA2 and GA5 genotypes approximated the
total population size of GB13 strains, balancing the population
sizes of HRSV-A and –B stable genotypes.
Discussion
Seasonal outbreaks of HRSV in Belgium have been document-
ed since the epidemic season of 1982–1983 [6,7,16]. Annually,
HRSV infections appear in October and reach a peak in
December. Remarkably, during the season of 2008–2009, the
peak incidence was observed in November. This earlier peak could
not be explained by meteorological parameters such as temper-
ature, humidity and the particulate matter concentrations in
ambient air [30]. Next to these factors, human behavior e.g.
indoor crowding and immunologic susceptibility e.g. level of
maternal antibodies, contribute to the seasonal character of these
outbreaks [31,32]. Children below the age of 12 months
represented 81.5% of the infected patients during the study. Here,
we also observed that HRSV is an important pathogen in
immunocompromised patients, resulting in prolonged virus
shedding. A total of 14 re-infections were observed during the
study period, where homologous subgroup (8/14) and heterolo-
gous subgroup (6/14) infections were detected (Table 2). For 3
homologous infections, secondary infection was caused by a strain
of the homologous genotype. Several amino acid substitutions
were detected between primary and secondary strains of the same
genotype suggesting that genetic variability may have resulted in
the escape to the immune response. Previous studies have reported
that strain-specific and group-specific immunity waned after 7 to 9
and 2 to 4 months respectively, allowing repeated infections to be
encountered [33,34].
During 10 consecutive seasons (1996–2006), a regular 3-yearly
cyclic pattern has been observed, where two HRSV-A dominant
seasons alternated with one HRSV-B season. Since the HRSV
Figure 4. Phylogenetic analysis of HRSV-B GB13 strains
designated to the BAIV lineage. The phylogenetic tree was
constructed based on a 762-nucleotide fragment of the G protein,
consisting of the two hypervariable regions. The nucleotide sequence of
the GB13 designated strains were compared to strains from Buenos
Aires (BA) and South Africa (SA) and assigned to branches of GB13. The
numbers at the internal nodes represent bootstrap values, determined
for 1000 iterations by the neighbour joining method. Only bootstrap
values .70 are indicated. The amino acid substitutions that originate
the main branches are indicated at the left of the nodes. Based on the
presence of a certain amino acid position, several clusters were
diversified. The red cluster groups the strains carrying the S267L
substitution. The strains of the dark blue cluster share the I281T and
T270I substitution. The cluster indicated in green groups the sequences
with the L219P substitution. The turquois coloured branch indicates the
sequences with the 2292G substitution. Within this cluster, sublineages
characterised by the E226D mutation and T289I mutation can be
distinguished. Brackets group strains with amino acid substitutions
associated with the origin of new sublineages of the GB13 genotype.
Strains with termination codon different from Q310STOP are indicated
by #. Strains that do not have the H287Y substitution are indicated by
single *. Strains indicated with **have the T270I substitution.
doi:10.1371/journal.pone.0060416.g004
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season of 2005/2006, this has changed into a yearly alternating
model where HRSV-A was replaced by HRSV-B in the
subsequent season. However, the HRSV-A dominance during
the 2010/2011 season introduced a second break of the subgroup
pattern possibly initiating a new alteration in the subgroup
periodicity. Overall, subgroup A strains (10/15) were dominating
more seasons than subgroup B strains (5/15).
For HRSV-A, GA2 and GA5 are genotypes that have been
circulating in the Belgian population since 1983–1984 [6]. For
HRSV-B, a replacement of a circulation pattern of multiple
genotypes (GB1-GB12) by the circulation of a single genotype
GB13 has occurred in 2003 [7,16]. For the GB13 gentoype, a
strong temporal clustering of the strains per epidemic season is
observed. The GB12 genotype was only circulating in the Belgian
population during the epidemic season of 2006/2007. All the
isolated GB13 strains belonged to the BAIV lineage. Other
genotypes such as the GA1, GA4 and BE/A1 genotype circulated
in the epidemic seasons of 1989/1990, 1992/1993 and 1986/
1987, respectively but have disappeared out of the Belgian
population. Also GB2, GB3, GB6, GB8, GB10 and GB11 have
not been isolated after the epidemic season of 2002/2003. The
GB13 genotype, first detected in Belgium in 2001/2002 has
replaced all other genotypes and co-circulated with GB12 in the
season 2002/2003 and 2006/2007. This gradual replacement of
circulating genotypes by GB13 has been observed in different
countries and GB13 represents 100% of the isolated HRSV-B
strains after 2006 [25,28]. Since 2006/2007, GA2 has been
predominating over GA5, whereas the genotype distribution
pattern of the previous seasons (1996/1997–2005/2006) demon-
strated annual or biennial replacement of GA5 by GA2 or vice
versa. GA2 and GA5 circulate worldwide and are recognized as
stable genotypes [24,25,28,35–40]. The select dominance of GA2
has also been observed in South Western China during epidemic
seasons 2006–2009 [40] and Central and South America [36],
Ireland in 2008/2009 [25] and South Africa in 2007–2008 [28].
The efficient circulation of these genotypes could not be explained
by high genetic variability of the carboxy-terminal hypervariable
region, since this region was remarkably conserved comparing
strains isolated over several years [41]. Amino acid analysis of
subgroup A strains suggested a predicted protein length of 297
residues for GA2 strains and a protein length of 298 amino acids
for GA5 strains. In addition, we identified 2 new amino acid
specific mutation of the GA2 genotype (A122 and Q156) and 7
new amino acid mutations (F102, I108, T111, I125, D161, S191
and L217) that differentiated the GA5 genotype from the GA2.
Recently, it has been speculated that the variation in the amino-
terminal variable region may be responsible for sustained virulence
and may have allowed its prolonged circulation. Until now, the
immunological importance of the amino-terminal variable region
remains to be elucidated [41]. However, the identification of 4
amino acid positions (237, 238, 244 and 262) under positive
selection, located in the second hypervariable region, is indicative
of diversifying selective pressure acting in this gene region.
Selective pressure by the immunological response has been
described as one of the mechanisms that drive genetic variability
of HRSV [42]. Strains that possess an asparagine at site 237 are
potentially N-glycosylated. Glycosylation is an important hallmark
of antigenicity of the virus, since it can mask or facilitate
recognition by antibodies of the immune response [26]. The
presence of an arginine at amino acid position 244 in isolates is
associated with the loss of reaction with monoclonal antibodies
[43]. For HRSV-B, 6 amino sites (73, 76, 83, 92, 139 and 151)
were under positive selection and these amino acids were all
located in the first hypervariable region of the G protein, except
Figure 5. Bayesian skyride plot. Demographic history of HRSV-A genotypes GA2 and GA5 is represented in blue and the HRSV-B GB13 genotype
is shown in purple. The population size (Net) is indicated on the y-axis and the x-axis demonstrates the time period in years. The inner line represents
the median estimate and the coloured areas in blue or purple indicate the 95% highest posterior density.
doi:10.1371/journal.pone.0060416.g005
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for amino acid 171, located in the conserved region. Immunologic
pressure seems to act mainly in the first hypervariable region and
the conserved region, which is remarkable. Not much is known
about the location of strain specific epitopes, however, immuno-
logical pressure acting in the conserved region is notable. The
amino acid found at a certain positive selected site varied between
strains, indicating the occurrence of ‘‘flip-flop’’ reversions over
time [26]. Further, the amino acid analysis of the HRSV-A G
protein supports this because almost all the GA2 specific mutations
reported by Botosso and co-workers reverted to their original
amino acid in the Belgian strains. Also amino acid position 237
that is under positive selection was described to be subject of
several flip-flop reversions. These flip-flop reversions are likely
responsible for the loss of protective immunity that may have been
evoked against key epitopes [26]. For HRSV-B, the reversion of
amino acid at position 171 in the HRSV-B GB13 strain
contributed to the re-infection with homologous genotype
(Table 2).
The G protein of HRSV-B isolates is polymorphic which can be
explained by the introduction of early stop codons, the alternating
use of 3 stop codons, the presence of a 60-nucleotide duplication,
6-nucleotide deletion and a novel 6-nucleotide insertion. These 6
nucleotides are probably inserted due to polymerase stuttering
during transcription or replication since these bases are flanked by
a guanosine combined with an adenosine cluster (Figure S2).
Remarkably, the first triplet of this insertion corresponds to the
position of the 3-nucleotide-insertion that has been reported for 5
Belgian isolates during the epidemic season of 1995/1996 that
clustered in the GB9 genotype. After this epidemic season, the 3-
nucleotide-insertion has disappeared out of the Belgian population
and now reappears, 14 epidemic years later, combined with a
second triplet, in GB13 strains. Most likely, these insertions
resulted from 2 separate mutational events. The polymorphism of
HRSV-B isolates has led to the prediction of protein lengths of
215, 235, 295, 296, 310, 312 and 317 residues, with G proteins of
310 amino acids being predominant.
The GB13 genotype can be subdivided in several branches BAI
to BAVI based on clustering with previous strains assigned to these
branches [27,28]. Belgian GB13 isolates circulating from 1999–
2005 were classified under 5 branches BAI-IV and BAVI [22]. All
the GB13 strains detected since 2006 belonged to the BAIV
branch. The spread of the BAIV lineage is observed worldwide
and suggests the successful transmission of the GB13 genotype.
Several amino acid substitutions located in the second hyper-
variable region of GB13 strains have been correlated with clusters
within the GB13 genotype. However, some BAII, -III and –V
specific amino acid substitutions were also detected in the Belgian
BAIV strains. A subdivision of the BAIV branch into 6 categories,
BAIVa, BAIVb, MAD-II, MAD-III, INDIA and BRAZIL, was
proposed based on detection of additional substitutions and
phylogenetic clustering [22]. In parallel, a different diversification
of the BAIV branch was reported, where BAIV was re-classified as
BAIV, BA7 to BA9 and a new genotype BA10 [29]. Although many
amino acid substitutions were detected among the Belgian strains, it
was not possible to correlate the amino acid substitutions to the (sub-
) branches. Because no sequence data is available that covers the
complete ectodomain of the G protein for strains of these
subclassifications, their implementation by means of phylogenetic
analysis was not possible.
GA2 and GA5 are genotypes that co-circulate worldwide, and
the predominance of the GB13 genotype has been reported for
several countries [28,40]. The demographic history of the
dominant HRSV-A genotypes and the predominant HRSV-B
genotype, reconstructed through a Bayesian skyride analysis
demonstrated a decrease in HRSV-A population size at the time
the GB13 expansion was levelled off (Figure 5). As a consequence
the HRSV-A population size was in balance with the HRSV-B
population around the epidemic season of 2004–2005. The
population size of GB13 is subsequently characterized by a
roughly constant population size that overlaps with the epidemi-
ological period where a yearly alternating subgroup dominance
was observed in Belgium. This study is the first to demonstrate that
the dissemination of the GB13 genotype may have led to a
decreased total population size of the GA2 and GA5 genotypes
worldwide resulting in a new equilibrium between of the total
HRSV-A and –B virus population. The proportional circulation of
these stable genotypes may be at the origin of the altered subgroup
pattern. However, more studies need to be conducted to support
this hypothesis.
Genetic mapping of the G protein gene remains important to
identify new genetically diverse HRSV variants that may spread
globally. This is illustrated by the identification of HRSV-B GB13
and the recently described HRSV-A ON1, two novel genotypes
containing a 60-nucleotide and 72-nucleotide duplication in the
second hypervariable region of the ectodomain [44]. The global
spread of GB13 is documented while for HRSV-A, it needs to be
awaited if the 72-nucleotide duplication will provide similar
transmission success. In addition, investigation of the genetic
diversity ensures the efficacy of the current vaccines and antiviral
compounds in development. The global spread of novel genotypes
may imply that the vaccines currently in development need to be
adjusted [28].
Supporting Information
Figure S1 The amino acid substitutions in the hypervariable
regions of HRSV-A GA2 and GA5 genotypes. The amino acid
substitutions in the hypervariable regions of HRSV-A GA2 and
GA5 genotypes. Deduced amino acid alignment of the G protein
gene from a selection of HRSV-A sequences isolated during 5
consecutive epidemic seasons (2006/2007–2010/2011). The
alignment is shown relative to the reference strain AUS/A2/61
(M11486). The amino acid residues depicted start at position 85 to
299. The conserved region is located at amino acid position 164–
176 with four cysteines at positions 173, 176, 182 and 186.
Identical residues or identical stopcodon positions to the reference
sequences are depicted as dots, and alternative used stop codons
are indicated by asterisk. GA2 genotype specific amino acid
mutations are indicated in yellow. GA5 specific amino acid
mutations are indicated in grey.
(EPS)
Figure S2 G protein polymorphisms of HRSV-B strains.
Schematic representation of the predicted G protein lengths for
the Belgian HRSV-B isolates in accordance with the WV/B1/85
reference strain. The G protein ectodomain consists of two
hypervariable regions separated by a central conserved region
(amino acid positions 153 to 221). The conserved region consists of
4 cysteine residues located between amino acids 164 and 187 and
are indicated by a dashed line. The underlined sequence
represents the used termination codon and the total protein length
is indicated at the end of each G protein. The 6-nucleotide
deletion is shown as a V, where the deleted amino acids are
indicated in top. The 60-nucleotide duplication region is visualised
as a paired black box, with the duplicated sequence indicated
above the box. The 6-nucleotide insertion is indicated as a little
black box. The insertion of premature stopcodons are visualised by
a dot (N) resulting in truncated G proteins.
(EPS)
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Table S1 HRSV-A sequence data used in the coalescent
analysis.
(DOCX)
Table S2 HRSV-B sequence data used in the coalescent
analysis.
(DOCX)
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